| Literature DB >> 10444237 |
J A Hey1, M Affrime, B Cobert, W Kreutner, F M Cuss.
Abstract
The extremely low reporting rate of cardiovascular adverse events for loratadine, the possible preferential use of loratadine in patients with pre-existing cardiovascular disorders, and the impressive lack of cardiovascular effects at extremely high concentrations in clinical and preclinical studies demonstrate the very safe cardiovascular profile of loratadine.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10444237 DOI： 10.1046/j.1365-2222.1999.0290s3197.x
Source DB: PubMed Journal: Clin Exp Allergy ISSN： 0954-7894 Impact factor: 5.018